Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + durvalumab for metastatic pancreatic cancer with DNA damage repair gene alterations
2024-510970-26-00Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Overall Response Rate. Started Nov 2022; status: completed.
02
Drugs
olaparibdurvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-510970-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510970-26-00.